No Data
BTIG Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Cuts Target Price to $9
Outlook Therapeutics Price Target Lowered to $9 From $50 at BTIG
Outlook Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Vigil Neuroscience Inc (VIGL) and Outlook Therapeutics (OTLK)
H.C. Wainwright Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Maintains Target Price $30
Outlook Therapeutics, Inc. (NASDAQ:OTLK): Is Breakeven Near?